home / stock / hook / hook news

HOOK News and Press, HOOKIPA Pharma Inc. From 03/24/22

Stock Information
Company Name: HOOKIPA Pharma Inc.
Stock Symbol: HOOK
Market: NASDAQ
Website: hookipapharma.com
Menu
HOOK HOOK Quote HOOK Short HOOK News HOOK Articles HOOK Message Board
Get HOOK Alerts

News, Short Squeeze, Breakout and More Instantly...
HOOK - IRBT, CENN and SPPI among pre market gainers

Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...
HOOK - HOOKIPA Pharma GAAP EPS of -$0.65 misses by $0.03, revenue of $3.9M beats by $0.11M

HOOKIPA Pharma press release (NASDAQ:HOOK): Q4 GAAP EPS of -$0.65 misses by $0.03. Revenue of $3.9M (-24.4% Y/Y) beats by $0.11M. The company expects to file an Investigational New Drug (IND) application for HB-300 in the third quarter of 2022. CEO comment: “With the recent capital rai...

HOOK - HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook

Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pem...

HOOK - Notable earnings before Thursday's open

OTCQX:CCHWF, CIH, OTCQX:CWBHF, DRI, FDS, HOOK, OTCQX:JUSHF, KC, MOMO, NEOG, SNX, TFFP, TITN, TMDI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

HOOK - Hoopika Pharma promotes internal candidate to Chief Scientific Officer role

Hoopika Pharma (NASDAQ:HOOK) has promoted Klaus Orlinger, Ph.D. to Chief Scientific Officer, most recently serving as Executive Vice President, Research. Since joining HOOKIPA in February 2012, Klaus has played a leading role in driving HOOKIPA’s arenaviral platform to the clinic ...

HOOK - HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer

NEW YORK and VIENNA, Austria, March 22, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Klaus Orlinger, Ph.D. has been promoted to ...

HOOK - HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022

NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full yea...
HOOK - HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitors Preclinical data suggest synergy of arenaviral immunotherapy with 4-1BB agonists or cell therapy, resulting in better tumor control...

HOOK - Organogenesis, CytomX top healthcare gainers; Karyopharm Bright Health lead losers' pack

Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...

HOOK - Telefonaktiebolaget LM Ericsson, First Solar, Golden Ocean Group among premarket losers' pack

Karyopharm Therapeutics (NASDAQ:KPTI) -29% after US Regulatory update on Selinexor in advanced or recurrent endometrial cancer. GoHealth (NASDAQ:GOCO) -24% on expecting Q4 revenue below estimates. Bright Health (NYSE:BHG) -10% on Q4 earnings release. Telefonaktie...
Previous 10 Next 10